Stroke is a major contributor to death and disability globally, and its burden will increase dramatically with ageing populations. The trajectories and determinants of cognitive impairment and functional outcomes after stroke are incompletely understood, particularly in lower income countries.
The PROSPECT platform will prospectively evaluate outcomes after stroke internationally, with integration of interventions and randomized controlled trials (RCTs) to improve cognitive and functional outcomes.
The co-primary outcomes of PROSPECT are cognitive and functional impairment.
The secondary outcomes include: quality of life, depression, fatigue, mortality, recurrent stroke and cardiovascular events, and other adverse events.
Participants will be followed for 5 years post stroke.
The platform will be used for sub-studies including imaging, genetic and biomarker analysis, and for embedded RCTs.
Prospective global platform
2022 - 2033
Raed Joundi is a stroke neurologist at Hamilton Health Sciences, Assistant Professor in the Department of Medicine (Division of Neurology) at McMaster University, and Investigator in the Brain Health research program at PHRI. His main academic interest is in evaluating and finding novel strategies to improve functional outcomes, quality of life, and cognition in people with cerebrovascular disease.
He obtained his undergraduate degree from the University of Manitoba, MD from Queen’s University, DPhil from Oxford University on a Rhodes Scholarship, and neurology residency training at the University of Toronto. He then completed a stroke fellowship and MSc in Clinical Epidemiology at the University of Calgary supported by a CIHR Fellowship Grant.
Mike Sharma, MD MSc FRCPC, is the Director of the Stroke Program at McMaster University and Hamilton Health Sciences and holds the Michael G DeGroote Chair in Stroke Prevention, at McMaster University in Hamilton, Canada. His research interests include the development of new antithrombotic treatments, incorporating magnetic resonance imaging endpoints into the design of stroke prevention trials and examining the effects of anticoagulants on stroke recurrence and covert brain infarcts.
He has led trials and sub-studies in large prevention trials focused on these areas including COMPASS MIND, NAVIGATE ESUS, DATAS II and currently leads as principal investigator, the global phase II AXIOMATIC-SSP trial investigating FXI inhibition for stroke prevention in 27 countries.
He has published more than 140 articles in referred journals, is the immediate past Chair of the Canadian Stroke Consortium, the professional organization for stroke physicians and clinical trialists in Canada and established the stroke program at the University of Ottawa. Dr. Sharma is committed to developing integrated processes for stroke care and developing human and system capacity for the next generation of stroke trials.
Dipika Desai oversees many epidemiologic studies, including the South Asian birth cohort, START, the South Asian Heart Risk Assessment (SAHARA), and the Canadian Alliance for Healthy Hearts and Minds (CAHHM), as well as management assistance and oversight in the utilization of samples from a number of other studies.
She has a Bachelor’s degree in Food and Nutrition from the M S University in Baroda, India, and a Master’s degree in Human Nutrition from the University of British Columbia.
Back To Top